Drug Trial Radar · NCT03573882
Study to Assess the Effect of Long-term Treatment With Voxelotor in Participants Who Have Completed Treatment in Study GBT440-031
Last checked: Nov 20, 2026Latest source record: Nov 18, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
179
Actual
Start
Jun 6, 2018
Primary completion
Nov 12, 2024
Study completion Nov 12, 2024
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Jun 29, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Open Label Extension Study of Voxelotor Clinical Trial Participants with Sickle Cell Disease Who Participated in Voxelotor Clinical Trials
Conditions
- Sickle Cell Disease
Interventions
VoxelotorDrug
300mg or 500mg Tablet, Oral, With or Without Food
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Sickle Cell Disease (SCD)-Related Treatment Emergent Adverse Events (TEAEs)Time frame: From date of informed consent up to 28 days after last dose of study drug (maximum up to 300.7 weeks)
- Number of Participants With Non- SCD-Related TEAEsTime frame: From date of informed consent up to 28 days after last dose of study drug (maximum up to 300.7 weeks)
- Number of Participants With SCD-Related Treatment Emergent Serious Adverse Events (TESAEs)Time frame: From date of informed consent up to 28 days after last dose of study drug (maximum up to 300.7 weeks)
- Number of Participants With Non-SCD-Related TESAEsTime frame: From date of informed consent up to 28 days after last dose of study drug (maximum up to 300.7 weeks)
- Annualized Incidence Rate (Events Per Person Years) of SCD-Related ComplicationsTime frame: From date of informed consent up to earlier of 28 days after last dose of study drug or end of study date (maximum up to 300.7 weeks)
- Annualized Incidence Rate (VOC Events Per Person Years) of On-Treatment Vaso-occlusive Crisis (VOCs)Time frame: From date of informed consent to last dose of study drug (maximum up to 296.7 weeks)
Locations
60 sites in 11 countries. Site status is shown where the registry gives one.
Arkansas Primary Care Clinic, PA
Little Rock, Arkansas
UCSF Benioff Children's Hospital Oakland
Oakland, California
Jackson Memorial Hospital (Investigational Drug Services)
Miami, Florida
Jackson Memorial Hospital
Miami, Florida
University of Miami Hospital & Clinics/SCCC, Research Pharmacy (Investigational Drug Services)
Miami, Florida
University of Miami
Miami, Florida
Children's Healthcare of Atlanta - Scottish Rite
Atlanta, Georgia
University of Illinois at Chicago Clinical Research Center
Chicago, Illinois
University of Illinois Hospital and Health Science System
Chicago, Illinois
Indiana Hemophilia and Thrombosis Center
Indianapolis, Indiana
St. Jude Affiliate Clinic Baton Rouge
Baton Rouge, Louisiana
Our Lady of the Lake Physician Group-Medical Oncology
Baton Rouge, Louisiana
University Medical Center New Orleans
New Orleans, Louisiana
Johns Hopkins University/Sickle Cell Infusion Center
Baltimore, Maryland
Brigham and Women's Hospital
Boston, Massachusetts
Brigham and Women's Hospital Research Pharmacy
Boston, Massachusetts
Dana Farber Cancer Institute
Boston, Massachusetts
Children's Hospital of Michigan
Detroit, Michigan
Newark Beth Israel Medical Center
Newark, New Jersey
Columbia University Medical Center - Herbert Irving Pavilion
New York, New York
Montefiore - Einstein Center for Cancer Care
The Bronx, New York
UNC Hospitals
Chapel Hill, North Carolina
Clinical and Translational Research Center (CTRC)
Chapel Hill, North Carolina
Duke University Medical Center
Durham, North Carolina
Investigational Drug Service, Duke University Hospital
Durham, North Carolina
Lynn Health Science Institute
Oklahoma City, Oklahoma
Thomas Jefferson University
Philadelphia, Pennsylvania
University of Pittsburgh Medical Center (UPMC)
Pittsburgh, Pennsylvania
Medical University of South Carolina - Comprehensive Sickle Cell Clinic
Charleston, South Carolina
Medical University of South Carolina: Investigational Drug Services Pharmacy
Charleston, South Carolina
Methodist Comprehensive Sickle Cell Clinic
Memphis, Tennessee
Texas Children's Hospital - Investigational Pharmacy
Houston, Texas
Texas Children's Hospital
Houston, Texas
Clinical Research Services Unit- Virginia Commonwealth University
Richmond, Virginia
Toronto General Hospital-University Health Network
Toronto, Ontario, Canada
Alexandria Clinical Research Center, Faculty of Medicine, Alexandria University
Alexandria, Egypt
Alexandria Clinical Research Center, Faculty of Medicine
Alexandria, Egypt
Zagazig University Hospital
Alsharkia, Egypt
Abu El Rich Hospital,Cairo University Hospital
Cairo, Egypt
Ain Shams University Hospital
Cairo, Egypt
Showing 40 of 60 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.